Fibrosis is an important component of large conduit artery disease in
hypertension. The endogenous tetrapeptide N-
acetyl-seryl-aspartyl-lysyl-proline (
Ac-SDKP) has anti-inflammatory and antifibrotic effects in the heart and kidney. However, it is not known whether
Ac-SDKP has an anti-inflammatory and antifibrotic effect on conduit arteries such as the aorta. We hypothesize that in ANG II-induced
hypertension Ac-SDKP prevents aortic
fibrosis and that this effect is associated with decreased
protein kinase C (PKC) activation, leading to reduced oxidative stress and
inflammation and a decrease in the profibrotic
cytokine transforming growth factor-beta1 (TGF-beta1) and phosphorylation of its second messenger Smad2. To test this hypothesis we used rats with ANG II-induced
hypertension and treated them with either vehicle or
Ac-SDKP. In this hypertensive model we found an increased
collagen deposition and
collagen type I and III
mRNA expression in the aorta. These changes were associated with increased PKC activation, oxidative stress,
intercellular adhesion molecule (ICAM)-1
mRNA expression, and macrophage infiltration.
TGF-beta1 expression and Smad2 phosphorylation also increased.
Ac-SDKP prevented these effects without decreasing blood pressure or aortic
hypertrophy.
Ac-SDKP also enhanced expression of inhibitory Smad7. These data indicate that in ANG II-induced
hypertension Ac-SDKP has an aortic antifibrotic effect. This effect may be due in part to inhibition of PKC activation, which in turn could reduce oxidative stress,
ICAM-1 expression, and macrophage infiltration. Part of the effect of
Ac-SDKP could also be due to reduced expression of the profibrotic
cytokine TGF-beta1 and inhibition of Smad2 phosphorylation.